Cited by 436Cardiovascular Function and Risk FactorsHeart Failure Treatment and ManagementCardiac Fibrosis and Remodeling

The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.

Research Priorities for Heart Failure With Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group Summary

Open access

Shah, Sanjiv J., Borlaug, Barry A., Kitzman, Dalane W., McCulloch, Andrew D., Blaxall, Burns C., Agarwal, Rajiv, Chirinos, Julio A., Collins, Sheila, Deo, Rahul C., Gladwin, Mark T., Granzier, Henk, Hummel, Scott L., Kass, David A., Redfield, Margaret M., Sam, Flora, Wang, Thomas J., Desvigne-Nickens, Patrice, Adhikari, Bishow B.·2020·Circulation

DOI 10.1161/circulationaha.119.041886PMC PMC7101072

Open this paper in CoChat — free account

Abstract

Heart failure with preserved ejection fraction (HFpEF), a major public health problem that is rising in prevalence, is associated with high morbidity and mortality and is considered to be the greatest unmet need in cardiovascular medicine today because of a general lack of effective treatments. To address this challenging syndrome, the National Heart, Lung, and Blood Institute convened a working group made up of experts in HFpEF and novel research methodologies to discuss research gaps and to prioritize research directions over the next decade. Here, we summarize the discussion of the working group, followed by key recommendations for future research priorities. There was uniform recognition that HFpEF is a highly integrated, multiorgan, systemic disorder requiring a multipronged investigative approach in both humans and animal models to improve understanding of mechanisms and treatment of HFpEF. It was recognized that advances in the understanding of basic mechanisms and the roles of inflammation, macrovascular and microvascular dysfunction, fibrosis, and tissue remodeling are needed and ideally would be obtained from (1) improved animal models, including large animal models, which incorporate the effects of aging and associated comorbid conditions; (2) repositories of deeply phenotyped physiological data and human tissue, made accessible to researchers to enhance collaboration and research advances; and (3) novel research methods that take advantage of computational advances and multiscale modeling for the analysis of complex, high-density data across multiple domains. The working group emphasized the need for interactions among basic, translational, clinical, and epidemiological scientists and across organ systems and cell types, leveraging different areas or research focus, and between research centers. A network of collaborative centers to accelerate basic, translational, and clinical research of pathobiological mechanisms and treatment strategies in HFpEF was discussed as an example of a strategy to advance research progress. This resource would facilitate comprehensive, deep phenotyping of a multicenter HFpEF patient cohort with standardized protocols and a robust biorepository. The research priorities outlined in this document are meant to stimulate scientific advances in HFpEF by providing a road map for future collaborative investigations among a diverse group of scientists across multiple domains.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1161/circulationaha.119.041886

Cites

114 of 114 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A Novel Paradigm for Heart Failure With Preserved Ejection Fraction
Paulus, W. J., & Tschöpe, C. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.092 · Cited by 3,564
Machine Learning in Medicine
Deo, R. C. (2015) · Circulation · doi:10.1161/circulationaha.115.001593 · Cited by 3,466
Heart Failure with Preserved and Reduced Ejection Fraction in Hemodialysis Patients: Prevalence, Disease Prediction and Prognosis
Antlanger, M., Aschauer, S., Kopecky, C., Hecking, M., Kovarik, J. J., Werzowa, J. M., Mascherbauer, J., Genser, B., Säemann, M. D., & Bonderman, D. (2017) · Kidney & Blood Pressure Research · doi:10.1159/000473868 · Cited by 2,808
Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908655 · Cited by 2,430
Self-citation
How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
Pieske, B. M., Tschöpe, C., de Boer, R. A., Fraser, A. G., Anker, S. D., Donal, E., Edelmann, F., Fu, M. L. X., Guazzi, M., Lam, C. S. P., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz641 · Cited by 1,961
A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction
Reddy, Y. N. V., Carter, R. E., Obokata, M., Redfield, M. M., & Borlaug, B. A. (2018) · Circulation · doi:10.1161/circulationaha.118.034646 · Cited by 1,294
Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction
Obokata, M., Reddy, Y. N. V., Pislaru, S. V., Melenovsky, V., & Borlaug, B. A. (2017) · Circulation · doi:10.1161/circulationaha.116.026807 · Cited by 1,179
Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction
González-López, E., Gallego‐Delgado, M., Guzzo-Merello, G., Moral, F. J. D. H.-D., Marcos, M. C., Robles, C., Bornstein, B., Salas, C., Lara‐Pezzi, E., Alonso‐Pulpón, L., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv338 · Cited by 1,176
Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction
Redfield, M. M., Chen, H. H., Borlaug, B. A., Semigran, M. J., Lee, K. L., Lewis, G. D., LeWinter, M. M., Rouleau, J. L., Bull, D. A., Mann, D. L., et al. (2013) · JAMA · doi:10.1001/jama.2013.2024 · Cited by 1,164
Phenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction
Shah, S. J., Katz, D. H., Selvaraj, S., Burke, M. A., Yancy, C. W., Gheorghiade, M., Bonow, R. O., Huang, C.-C., & Deo, R. C. (2015) · Circulation · doi:10.1161/circulationaha.114.010637 · Cited by 1,157

Flagged first, then by citations

Show all 114 references

Sorted by citations

Heart Failure With Preserved Ejection Fraction: A Review
Redfield, M. M., & Borlaug, B. A. (2023) · JAMA · doi:10.1001/jama.2023.2020 · Cited by 662
Cellular and molecular pathobiology of heart failure with preserved ejection fraction
Mishra, S., & Kass, D. A. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00480-6 · Cited by 437
From Systemic Inflammation to Myocardial Fibrosis
Paulus, W. J., & Zile, M. R. (2021) · Circulation Research · doi:10.1161/circresaha.121.318159 · Cited by 413
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials
Butler, J., Shah, S. J., Petrie, M. C., Borlaug, B. A., Abildstrøm, S. Z., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Verma, S., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00469-0 · Cited by 386
Obesity cardiomyopathy: evidence, mechanisms, and therapeutic implications
Ren, J. T., Wu, N. N., Wang, S., Sowers, J. R., & Zhang, Y. (2021) · Physiological Reviews · doi:10.1152/physrev.00030.2020 · Cited by 388
Myocardial Gene Expression Signatures in Human Heart Failure With Preserved Ejection Fraction
Hahn, V. S., Knutsdottir, H., Luo, X., Bedi, K., Margulies, K. B., Haldar, S. M., Stolina, M., Yin, J., Khakoo, A. Y., Vaishnav, J., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.050498 · Cited by 291
Self-citation
Metabolic inflammation in heart failure with preserved ejection fraction
Schiattarella, G. G., Rodolico, D., & Hill, J. A. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa217 · Cited by 284
Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial
Shah, S. J., Borlaug, B. A., Chung, E. S., Cutlip, D. E., Debonnaire, P., Fail, P. S., Gao, Q., Hasenfuss, G. P., Kahwash, R., Kaye, D. M., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00016-2 · Cited by 284
High-Throughput Precision Phenotyping of Left Ventricular Hypertrophy With Cardiovascular Deep Learning
Duffy, G., Cheng, P. P., Yuan, N., He, B. D., Kwan, A. C., Shun-Shin, M. J., Alexander, K. M., Ebinger, J. E., Lungren, M. P., Rader, F., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2021.6059 · Cited by 252
Heart Failure with Preserved Ejection Fraction: Mechanisms and Treatment Strategies
Omote, K., Verbrugge, F. H., & Borlaug, B. A. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042220-022745 · Cited by 232
Heart Failure With Preserved Ejection Fraction: Heterogeneous Syndrome, Diverse Preclinical Models
Roh, J. D., Hill, J. A., Singh, A. S. C., Valero‐Muñoz, M., & Sam, F. (2022) · Circulation Research · doi:10.1161/circresaha.122.320257 · Cited by 202
Exercise Intolerance in Older Adults With Heart Failure With Preserved Ejection Fraction
Pandey, A., Shah, S. J., Butler, J., Kellogg, D. L., Lewis, G. D., Forman, D. E., Mentz, R. J., Borlaug, B. A., Simon, M. A., Chirinos, J. A., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.07.014 · Cited by 184
Heart failure with preserved ejection fraction
HAMO, C. E., DeJong, C., Hartshorne‐Evans, N., Lund, L. H., Shah, S. J., Solomon, S. D., & Lam, C. S. P. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00540-y · Cited by 197
Abdominal ultrasound in the assessment of extent and activity of Crohn's disease: clinical significance and implication of bowel wall thickening.
Maconi, G., Parente, F., Bollani, S., Cesana, B. M., & Porro, G. B. (1996) · PubMed · Cited by 177
Diagnosis of Heart Failure With Preserved Ejection Fraction Among Patients With Unexplained Dyspnea
Reddy, Y. N. V., Kaye, D. M., Handoko, M. L., van de Bovenkamp, A. A., Tedford, R. J., Keck, C., Andersen, M. J., Sharma, K., Trivedi, R. K., Carter, R. E., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.1916 · Cited by 178
Pulmonary Hypertension in HFpEF and HFrEF
Guazzi, M., Ghio, S., & Adir, Y. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.06.069 · Cited by 149
Immunometabolic mechanisms of heart failure with preserved ejection fraction
Schiattarella, G. G., Alcaide, P., Condorelli, G., Gillette, T. G., Heymans, S. R. B., Jones, E. A. V., Kallikourdis, M., Lichtman, A. H., Marelli‐Berg, F. M., Shah, S. J., et al. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-022-00032-w · Cited by 137
Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure
Borlaug, B. A., Blair, J., Bergmann, M. W., Bugger, H., Burkhoff, D., Bruch, L., Celermajer, D. S., Claggett, B. L., Cleland, J. G. F., Cutlip, D. E., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.059486 · Cited by 131
Albuminuria and Heart Failure
Khan, M. S., Shahid, I., Anker, S. D., Fonarow, G. C., Fudim, M., Hall, M. E., Hernandez, A. F., Morris, A. A., Shafi, T., Weir, M. R., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.10.028 · Cited by 136
Supervised Exercise Training for Chronic Heart Failure With Preserved Ejection Fraction: A Scientific Statement From the American Heart Association and American College of Cardiology
Sachdev, V., Sharma, K., Keteyian, S. J., Alcain, C. F., Desvigne-Nickens, P. M., Fleg, J. L., Florea, V. G., Franklin, B. A., Guglin, M. E., Halle, M., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001122 · Cited by 144
A Simple Score to Identify Increased Risk of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction
Davies, D. R., Redfield, M. M., Scott, C. G., Minamisawa, M., Grogan, M. A., Dispenzieri, A. A., Chareonthaitawee, P., Shah, A. M., Shah, S. J., Wehbe, R. M., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.1781 · Cited by 136
Obesity, venous capacitance, and venous compliance in heart failure with preserved ejection fraction
Sorimachi, H., Burkhoff, D., Verbrugge, F. H., Omote, K., Obokata, M., Reddy, Y. N. V., Takahashi, N., Sunagawa, K., & Borlaug, B. A. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2254 · Cited by 124
Self-citation
An evidence-based screening tool for heart failure with preserved ejection fraction: the HFpEF-ABA score
Reddy, Y. N. V., Carter, R. E., Sundaram, V., Kaye, D. M., Handoko, M. L., Tedford, R. J., Andersen, M. J., Sharma, K., Obokata, M., Verbrugge, F. H., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03140-1 · Cited by 119
SIRT6 Mitigates Heart Failure With Preserved Ejection Fraction in Diabetes
Wu, X., Liu, H., Brooks, A. C., Xu, S., Luo, J., Steiner, R., Mickelsen, D. M., Moravec, C. S., Alexis, J. D., Small, E. M., et al. (2022) · Circulation Research · doi:10.1161/circresaha.121.318988 · Cited by 98
Signaling cascades in the failing heart and emerging therapeutic strategies
He, X., Du, T., Long, T., Liao, X., Dong, Y., & Huang, Z. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00972-6 · Cited by 108
Rehabilitation Intervention in Older Patients With Acute Heart Failure With Preserved Versus Reduced Ejection Fraction
Mentz, R. J., Whellan, D. J., Reeves, G. R., Pastva, A. M., Duncan, P. W., Upadhya, B., Nelson, M. B., Chen, H., Reed, S. D., Rosenberg, P. B., et al. (2021) · JACC Heart Failure · doi:10.1016/j.jchf.2021.05.007 · Cited by 95
Genetic architecture of heart failure with preserved versus reduced ejection fraction
Joseph, J., Liu, C., Hui, Q., Aragam, K. G., Wang, Z., CHAREST, B. R., Huffman, J. E., Keaton, J. M., Edwards, T. L., Demissie, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35323-0 · Cited by 79
Extracardiac Abnormalities of Preload Reserve
Fudim, M., Sobotka, P. A., & Dunlap, M. E. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.007308 · Cited by 73
Large Animal Models of Heart Failure
Silva, K. A. S., & Emter, C. A. (2020) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2020.04.011 · Cited by 73
Mechanisms of Sinoatrial Node Dysfunction in Heart Failure With Preserved Ejection Fraction
Mesquita, T., Zhang, R., Cho, J. H., Zhang, R., Lin, Y.-N., Sanchez, L., Goldhaber, J. I., Yu, J. K., Liang, J. A., Liu, W., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.054976 · Cited by 68
Heart failure with preserved ejection fraction diagnosis and treatment: An updated review of the evidence
Buono, M. G. D., Iannaccone, G., Scacciavillani, R., Carbone, S., Camilli, M., Niccoli, G., Borlaug, B. A., Lavie, C. J., Arena, R. A., Crea, F., et al. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.04.011 · Cited by 70
Endotrophin, a Collagen VI Formation–Derived Peptide, in Heart Failure
Chirinos, J. A., Zhao, L., Reese‐Petersen, A. L., Cohen, J. B., Genovese, F., Richards, M., Doughty, R. N., Dı́ez, J., González, A., Querejeta, R., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2200091 · Cited by 62
Understanding the Pathobiology of Pulmonary Hypertension Due to Left Heart Disease
Huston, J., & Shah, S. J. (2022) · Circulation Research · doi:10.1161/circresaha.122.319967 · Cited by 61
Transcutaneous Vagus Nerve Stimulation Ameliorates the Phenotype of Heart Failure With Preserved Ejection Fraction Through Its Anti-Inflammatory Effects
Elkholey, K., Niewiadomska, M., Morris, L. M., Whyte, S., Houser, J. S., Humphrey, M. B., & Stavrakis, S. (2022) · Circulation Heart Failure · doi:10.1161/circheartfailure.122.009288 · Cited by 60
Cardiac mechanostructure: Using mechanics and anisotropy as inspiration for developing epicardial therapies in treating myocardial infarction
Dwyer, K. D., & Coulombe, K. L. K. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.12.015 · Cited by 61
Early Protective Role of Inflammation in Cardiac Remodeling and Heart Failure: Focus on TNFα and Resident Macrophages
BESSE, S., Nadaud, S., Balse, E., & Pavoine, C. (2022) · Cells · doi:10.3390/cells11071249 · Cited by 60
Genome-wide association study meta-analysis provides insights into the etiology of heart failure and its subtypes
Henry, A., Mo, X., Finan, C., Chaffin, M. D., Speed, D., Issa, H. G., Denaxas, S., Ware, J. S., Zheng, S. L., Mälarstig, A., et al. (2025) · Nature Genetics · doi:10.1038/s41588-024-02064-3 · Cited by 71
Iron Deficiency: Impact on Functional Capacity and Quality of Life in Heart Failure with Preserved Ejection Fraction
Alcaide-Aldeano, A., Garay, A., Alcoberro, L., Jiménez‐Marrero, S., Yun, S., Tajes, M., García‐Romero, E., Díez‐López, C., González‐Costello, J., Mateus-Porta, G., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041199 · Cited by 63
Renal Denervation to Treat Heart Failure
Sharp, T. E., & Lefer, D. J. (2020) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-093431 · Cited by 56
Characterization of Cardiac Sympathetic Nervous System and Inflammatory Activation in HFpEF Patients
Kaye, D. M., Nanayakkara, S., Wang, B., Shihata, W., Marques, F. Z., Esler, M., Lambert, G. W., & Mariani, J. A. (2022) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.11.007 · Cited by 57
Inflammageing, a targetable pathway for preventing cardiovascular diseases
Aranda, J. F., Ramírez, C. M., & Mittelbrunn, M. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae240 · Cited by 64
Circulating Vascular Cell Adhesion Molecule‐1 and Incident Heart Failure: The Multi‐Ethnic Study of Atherosclerosis (MESA)
Patel, R. B., Colangelo, L. A., Bielinski, S. J., Larson, N. B., Ding, J., Allen, N. B., Michos, E. D., Shah, S. J., & Lloyd‐Jones, D. M. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.019390 · Cited by 56
Psychological stress in heart failure: a potentially actionable disease modifier
Harris, K. M., Jacoby, D. L., Lampert, R. J., Soucier, R. J., & Burg, M. M. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-10056-8 · Cited by 62
NADPH Oxidases in Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction
Teuber, J. P., Essandoh, K., Hummel, S. L., Madamanchi, N. R., & Brody, M. J. (2022) · Antioxidants · doi:10.3390/antiox11091822 · Cited by 55
Therapeutic inhibition of RBM20 improves diastolic function in a murine heart failure model and human engineered heart tissue
Radke, M. H., Lisakowski, V. B., Britto‐Borges, T., Kubli, D. A., Jüttner, R., Parakkat, P., Carballo, J. L., Huettemeister, J., Liss, M., Hansen, A., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe8952 · Cited by 50
Myeloid Cell Derived IL1β Contributes to Pulmonary Hypertension in HFpEF
Agrawal, V., Kropski, J. A., Gokey, J. J., Kobeck, E., Murphy, M. B., Murray, K. T., Fortune, N. L., Moore, C. S., Meoli, D. F., Monahan, K., et al. (2023) · Circulation Research · doi:10.1161/circresaha.123.323119 · Cited by 52
Novel Göttingen Miniswine Model of Heart Failure With Preserved Ejection Fraction Integrating Multiple Comorbidities
Sharp, T. E., Scarborough, A. L., Li, Z., Polhemus, D. J., Hidalgo, H. A., Schumacher, J., Matsuura, T. R., Jenkins, J. S., Kelly, D. P., Goodchild, T. T., et al. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2020.11.012 · Cited by 52
Discovery of Titin and Its Role in Heart Function and Disease
Granzier, H. L. M., & Labeit, S. (2025) · Circulation Research · doi:10.1161/circresaha.124.323051 · Cited by 55
What’s wrong with my experiment?: The impact of hidden variables on neuropsychopharmacology research
Butler-Struben, H. M., Kentner, A. C., & Trainor, B. C. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01309-1 · Cited by 50
Right Heart Phenotype in Heart Failure With Preserved Ejection Fraction
Guazzi, M., & Naeije, R. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.007840 · Cited by 49
Rationale and Design of ENDEAVOR: A Sequential Phase 2b–3 Randomized Clinical Trial to Evaluate the Effect of Myeloperoxidase Inhibition on Symptoms and Exercise Capacity in Heart Failure with Preserved or Mildly Reduced Ejection Fraction
Lund, L. H., Lam, C. S. P., Pizzato, P. E., Gabrielsen, A., Michaëlsson, E., Nelander, K., Ericsson, H., Holden, J., Folkvaljon, F., Mattsson, A., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2977 · Cited by 48
The role of epicardial adipose tissue remodelling in heart failure with preserved ejection fraction
Janssen-Telders, C., Eringa, E. C., de Groot, J. R., de Man, F. S., & Handoko, M. L. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf056 · Cited by 57
Pathophysiology of Heart Failure with Preserved Ejection Fraction
Youn, J.-C., Ahn, Y., & Jung, H. O. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.02.001 · Cited by 45
Supervised Exercise Training for Chronic Heart Failure With Preserved Ejection Fraction: A Scientific Statement From the American Heart Association and American College of Cardiology
Sachdev, V., Sharma, K., Keteyian, S. J., Alcain, C. F., Desvigne-Nickens, P. M., Fleg, J. L., Florea, V. G., Franklin, B. A., Guglin, M. E., Halle, M., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.02.012 · Cited by 45
Uncovering Unrecognized Heart Failure With Preserved Ejection Fraction Among Individuals With Obesity and Dyspnea
Kosyakovsky, L. B., Liu, E. E., Wang, J. K., Myers, L., Parekh, J. K., Knauss, H., Lewis, G. D., Malhotra, R., Nayor, M., Robbins, J. M., et al. (2024) · Circulation: Heart Failure · doi:10.1161/circheartfailure.123.011366 · Cited by 43
Differential sex-dependent susceptibility to diastolic dysfunction and arrhythmia in cardiomyocytes from obese diabetic heart failure with preserved ejection fraction model
Hernández, J. M., Shen, E. Y., Ko, C. Y., Hourani, Z., Spencer, E. R., Smoliarchuk, D., Bossuyt, J., Granzier, H. L. M., Bers, D. M., & Hegyi, B. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae070 · Cited by 42
Diastolic dysfunction and sex-specific progression to HFpEF: current gaps in knowledge and future directions
van Ommen, A. M. L. N., Canto, E. D., Cramer, M. J., Rutten, F. H., Onland‐Moret, N. C., & den Ruijter, H. M. (2022) · BMC Medicine · doi:10.1186/s12916-022-02650-4 · Cited by 40
Empagliflozin protects against heart failure with preserved ejection fraction partly by inhibiting the senescence-associated STAT1–STING axis
Shi, Y., Zhao, L., Wang, J., Liu, X., Bai, Y., Cong, H., & Li, X. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02366-0 · Cited by 40
Echocardiography in the diagnostic evaluation and phenotyping of heart failure with preserved ejection fraction
Harada, T., Kagami, K., Kato, T., & Obokata, M. (2021) · Journal of Cardiology · doi:10.1016/j.jjcc.2021.11.003 · Cited by 45
Unsupervised Machine Learning for Assessment of Left Ventricular Diastolic Function and Risk Stratification
Chao, C., Kato, N., Scott, C. G., López-Jiménez, F. A., Lin, G., Kane, G. C., & Pellikka, P. A. (2022) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2022.06.013 · Cited by 40
The Association of Protein Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction
Takvorian, K. S., Wang, D., Courchesne, P. L., Vasan, R. S., Benjamin, E. J., Cheng, S. C., Larson, M. G., Levy, D. A., & Ho, J. E. (2022) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.009446 · Cited by 42
External validation of artificial intelligence for detection of heart failure with preserved ejection fraction
Akerman, A. P., Al-Roub, N., Angell-James, C. E. M., Cassidy, M. A., Thompson, R. A. M., Bosque, L., Rainer, K., Hawkes, W., Piotrowska, H., Leeson, P., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58283-7 · Cited by 41
Body Mass Index and Cardiorenal Outcomes in the EMPEROR-Preserved Trial: Principal Findings and Meta-Analysis with the DELIVER Trial
Sattar, N. A., Butler, J., Lee, M. M. Y., Harrington, J., Sharma, A., Zannad, F. M., Filippatos, G. S., Verma, S., Januzzi, J. L., Ferreira, J. P., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3221 · Cited by 42
Genomic, Proteomic, and Metabolic Comparisons of Small Animal Models of Heart Failure With Preserved Ejection Fraction: A Tale of Mice, Rats, and Cats
Smith, A., Altara, R., Amin, G., Habeichi, N. J., Thomas, D. G., Jun, S., Kaplan, A., Booz, G. W., & Zouein, F. A. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.026071 · Cited by 39
Diabetes and Excess Aldosterone Promote Heart Failure With Preserved Ejection Fraction
Hegyi, B., Hernández, J. M., Ko, C. Y., Hong, J., Shen, E. Y., Spencer, E. R., Smoliarchuk, D., Navedo, M. F., Bers, D. M., & Bossuyt, J. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.027164 · Cited by 39
Periodontal Status, C-Reactive Protein, NT-proBNP, and Incident Heart Failure
Molinsky, R. L., yuzefpolskaya, M., Norby, F. L., Yu, B., Shah, A. M., Pankow, J. S., Ndumele, C. E., Lutsey, P. L., Papapanou, P. N., Beck, J. D., et al. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2022.05.008 · Cited by 35
Contemporary Evidence and Practice on Right Heart Catheterization in Patients with Acute or Chronic Heart Failure
Manzi, L., Sperandeo, L., Forzano, I., Castiello, D. S., Florimonte, D., Paolillo, R., Santoro, C., Mancusi, C., Serafino, L. D., Esposito, G., et al. (2024) · Diagnostics · doi:10.3390/diagnostics14020136 · Cited by 36
Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
Ostrominski, J. W., Vaduganathan, M., Claggett, B. L., de Boer, R. A., Desai, A. S., Dobreanu, D., Hernandez, A. F., Inzucchi, S. E., Jhund, P. S., Kosiborod, M., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2652 · Cited by 36
Berberine alleviates myocardial diastolic dysfunction by modulating Drp1-mediated mitochondrial fission and Ca2+ homeostasis in a murine model of HFpEF
Abudureyimu, M., Yang, M., Wang, X., Luo, X., Ge, J., Hu, P., Zhang, Y., & Ren, J. T. (2023) · Frontiers of Medicine · doi:10.1007/s11684-023-0983-0 · Cited by 33
Peripheral and pulmonary effects of inorganic nitrite during exercise in heart failure with preserved ejection fraction
Reddy, Y. N. V., Stewart, G. M., Obokata, M., Koepp, K. E., & Borlaug, B. A. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2093 · Cited by 33
The future of heart failure with preserved ejection fraction
Heinzel, F. R., & Shah, S. J. (2022) · Herz · doi:10.1007/s00059-022-05124-8 · Cited by 36
Association between proteomic biomarkers and myocardial fibrosis measured by MRI: the multi-ethnic study of atherosclerosis
Bakhshi, H., Michelhaugh, S. A., Bruce, S. A., Seliger, S. L., Qian, X., Ambale‐Venkatesh, B., Varadarajan, V., Bagchi, P., Lima, J. A. C., & deFilippi, C. R. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104490 · Cited by 35
Inhibition of the extracellular enzyme A disintegrin and metalloprotease with thrombospondin motif 4 prevents cardiac fibrosis and dysfunction
Vistnes, M., Erusappan, P. M., Sasi, A., Nordén, E. S., Bergo, K. K., Romaine, A., Lunde, I. G., Zhang, L., Olsen, M. B., Øgaard, J., et al. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad078 · Cited by 32
Endothelial-Mesenchymal Transition in Heart Failure With a Preserved Ejection Fraction
Valero‐Muñoz, M., Oh, A., Faudoa, E., Bretón‐Romero, R., El-Adili, F., Bujor, A. M., & Sam, F. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.008372 · Cited by 31
Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction
Omote, K., & Borlaug, B. A. (2021) · Circulation Journal · doi:10.1253/circj.cj-21-0795 · Cited by 32
Impaired Right Atrial Reserve Function in Heart Failure with Preserved Ejection Fraction
Kagami, K., Harada, T., Yoshida, K., Amanai, S., Kato, T., Wada, N., Adachi, T. K., & Obokata, M. (2022) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2022.03.006 · Cited by 30
Cardiac Power Output Is Independently and Incrementally Associated With Adverse Outcomes in Heart Failure With Preserved Ejection Fraction
Harada, T., Yamaguchi, M., Omote, K., Iwano, H., Mizuguchi, Y., Amanai, S., Yoshida, K., Kato, T., Kurosawa, K., Nagai, T., et al. (2022) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.121.013495 · Cited by 30
Clinical Implications of Plasma Galectin-3 in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis
Shi, Y., Dong, G., Liu, J., Xiong, S., Liu, C., Yang, C., Wang, Q., & Qiao, W. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.854501 · Cited by 30
Heart failure with mildly reduced and preserved ejection fraction: A review of disease burden and remaining unmet medical needs within a new treatment landscape
Desai, N. R., Olewińska, E., Famulska, A., Rémuzat, C., François, C., & Folkerts, K. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10385-y · Cited by 36
Nrf2-Keap1 in Cardiovascular Disease: Which Is the Cart and Which the Horse?
Dhyani, N., Tian, C., Gao, L., Rudebush, T., & Zucker, I. H. (2024) · Physiology · doi:10.1152/physiol.00015.2024 · Cited by 30
Cardiovascular, Kidney, Liver, and Metabolic Interactions in Heart Failure: Breaking Down Silos
Lee, C. J. M., Kosyakovsky, L. B., Khan, M. S., Wu, F., Chen, G., Hill, J. A., Ho, J. E., Foo, R., & Zannad, F. M. (2025) · Circulation Research · doi:10.1161/circresaha.125.325602 · Cited by 33
Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond
Morfino, P., Aimo, A., Castiglione, V., Vergaro, G., Emdin, M., & Clerico, A. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9080256 · Cited by 31
Non-invasive assessment of HFpEF in mouse models: current gaps and future directions
Villalba‐Orero, M., García‐Pavía, P., & Lara‐Pezzi, E. (2022) · BMC Medicine · doi:10.1186/s12916-022-02546-3 · Cited by 29
Increased Capillary Permeability in Heart Induces Diastolic Dysfunction Independently of Inflammation, Fibrosis, or Cardiomyocyte Dysfunction
Abélanet, A., Camoin, M., Rubin, S., Bougaran, P., Delobel, V., Pernot, M., Forfar, I., Guilbeau‐Frugier, C., Galès, C., Bats, M., et al. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.317319 · Cited by 31
Educational approaches for patients with heart surgery: a systematic review of main features and effects
Shahmoradi, L., Rezaei, N., Rezayi, S., Zolfaghari, M., & Manafi, B. (2022) · BMC Cardiovascular Disorders · doi:10.1186/s12872-022-02728-0 · Cited by 28
Functional Roles of Furin in Cardio-Cerebrovascular Diseases
Wichaiyo, S., Koonyosying, P., & Morales, N. P. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00325 · Cited by 26
Echocardiographic Predictors of Cardiovascular Outcome in Heart Failure with Preserved Ejection Fraction
Wang, N., Rueter, P., Ng, M., Chandramohan, S., Hibbert, T., O’Sullivan, J., Kaye, D. M., & Lal, S. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3271 · Cited by 27
Heterogeneity in Heart Failure with Preserved Ejection Fraction: A Systematic Review of Phenotypic Classifications and Clinical Implications
Epelde, F. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14144820 · Cited by 32
Growth hormone-releasing hormone agonists ameliorate chronic kidney disease-induced heart failure with preserved ejection fraction
Rieger, A. C., Bagno, L., Salerno, A. G., Florea, V., Rodriguez, J. E., Rosado, M., Turner, D., Dulce, R. A., Takeuchi, L. M., Kanashiro‐Takeuchi, R. M., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2019835118 · Cited by 27
Risk Factors and Prediction Models for Incident Heart Failure with Reduced and Preserved Ejection Fraction
Gaziano, L., Cho, K., Djoussé, L., Schubert, P. L., Galloway, A., Ho, Y.-L. A., Kurgansky, K. E., GAGNON, D. R., Russo, J. P., Angelantonio, E. D., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13429 · Cited by 26
Skeletal Muscle SIRT3 Deficiency Contributes to Pulmonary Vascular Remodeling in Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction
Jheng, J.-R., Bai, Y., Noda, K., Huot, J. R., Cook, T. G., Fisher, A. J., Chen, Y.-Y., Goncharov, D. A., Goncharova, E. A., Simon, M. A. M., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.068624 · Cited by 26
Lifestyle interventions in cardiometabolic HFpEF: dietary and exercise modalities
Vacca, A., Wang, R., Nambiar, N., Capone, F., Farrelly, C., Mostafa, A., Sechi, L. A., & Schiattarella, G. G. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10439-1 · Cited by 32
Synthetic growth hormone-releasing hormone agonist ameliorates the myocardial pathophysiology characteristic of heart failure with preserved ejection fraction
Dulce, R. A., Kanashiro‐Takeuchi, R. M., Takeuchi, L. M., Salerno, A. G., Wanschel, A. C. B. A., Kulandavelu, S., Balkan, W., Zuttion, M. S. S. R., Cai, R., Schally, A. V., et al. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac098 · Cited by 27
Left Ventricular Gene Expression in Heart Failure With Preserved Ejection Fraction—Profibrotic and Proinflammatory Pathways and Genes
Ye, B., Bradshaw, A. D., Abrahante, J. E., Dragon, J. A., Häußler, T. N., Bell, S., Hirashima, F., LeWinter, M. M., Zile, M. R., & Meyer, M. (2023) · Circulation Heart Failure · doi:10.1161/circheartfailure.123.010395 · Cited by 25
Subtypes identification on heart failure with preserved ejection fraction via network enhancement fusion using multi-omics data
Wu, Y., Wang, H. H., Li, Z., Cheng, J., Fang, R., Cao, H., & Cui, Y. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.03.010 · Cited by 25
Telmisartan ameliorates cardiac fibrosis and diastolic function in cardiorenal heart failure with preserved ejection fraction
Chang, D., Xu, T., Zhang, S.-J., Cai, Y., Min, S., Zhao, Z., Lu, C., Wang, Y., & Ju, S. (2021) · Experimental Biology and Medicine · doi:10.1177/15353702211035058 · Cited by 26
Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Zhou, H., Peng, W., Li, F., Wang, Y., Wang, B., Ding, Y., Lin, Q., Zhao, Y., Pan, G., & Wang, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.875327 · Cited by 31
Interplay of the heart, spleen, and bone marrow in heart failure: the role of splenic extramedullary hematopoiesis
Hiraiwa, H., Yura, Y., Okumura, T., & Murohara, T. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10418-6 · Cited by 23
The aging heart in focus: The advanced understanding of heart failure with preserved ejection fraction
Zhang, Z.-W., Wang, Y., Chen, X., Wu, C., Zhou, J., Chen, Y., Liu, X., & Tang, X. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102542 · Cited by 24
Circulating Non-Coding RNAs as Indicators of Fibrosis and Heart Failure Severity
Boichenko, V., Noakes, V. M., Reilly-O’Donnell, B., Luciani, G. B., Emanueli, C., Martelli, F., & Gorelik, J. (2025) · Cells · doi:10.3390/cells14070553 · Cited by 23

Authors: Shah, S. J., Borlaug, B. A., Kitzman, D. W., McCulloch, A. D., Blaxall, B. C., Agarwal, R., Chirinos, J. A., Collins, S., Deo, R. C., Gladwin, M. T., Granzier, H., Hummel, S. L., Kass, D. A., Redfield, M. M., Sam, F., Wang, T. J., Desvigne-Nickens, P., & Adhikari, B. B.
Affiliations: Northwestern University (US)
Mayo Clinic (US)
Wake Forest University Health Sciences (US)
University of California San Diego (US)
Christ Hospital (US)
Indiana University Indianapolis (US)
University of Pennsylvania (US)
Vanderbilt University (US)
Brigham and Women's Hospital (US)
University of Pittsburgh (US)
University of Arizona (US)
University of Michigan (US)
Johns Hopkins University (US)
Boston University (US)
National Institutes of Health (US)
ORCID: Shah, Sanjiv J.
Borlaug, Barry A.
Kitzman, Dalane W.
McCulloch, Andrew D.
Agarwal, Rajiv
Chirinos, Julio A.
Collins, Sheila
Deo, Rahul C.
Gladwin, Mark T.
Granzier, Henk
Hummel, Scott L.
Kass, David A.
Redfield, Margaret M.
Sam, Flora
Wang, Thomas J.
Desvigne-Nickens, Patrice
Venue: Circulation
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2020-03-24
Volume: 141
Issue: 12
Pages: 1001-1026
ISSN: 0009-7322 (ISSN-L)
1524-4539
DOI: 10.1161/circulationaha.119.041886
PMC: PMC7101072
OpenAlex: W3012616651
Cited by: 436
References: 114
Citations by year: 2026: 53 · 2025: 74 · 2024: 74 · 2023: 67 · 2022: 99 · 2021: 49 · 2020: 19
FWCI: 9.93
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Circulation (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute on Aging (R01AG018915, R01AG045551, R01AG058969, P30AG021332, U24AG059624)
National Heart, Lung, and Blood Institute (R01HL128526, R61HL146390, R01HL118524, U01HL125175, R01HL127028, R01HL144657, R01HL104106, R01HL126638, U10HL110262, R01HL149423, DP2HL123228, R35HL135827, P01HL103455, R01HL117153, R01HL140731, P01HL094307, R01HL132551, U01HL125205, R01HL133695, R01HL121510, R01HL107577, R56HL136730, R01HL134321, R01HL125886, R01HL098032, T32HL110849)
National Cancer Institute (K12CA090625)
National Institute of Diabetes and Digestive and Kidney Diseases (R01DK103056, P50DK096418)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
Keywords: heart failure with preserved ejection fraction, research priorities, research gaps, animal models, inflammation, microvascular dysfunction, macrovascular dysfunction, fibrosis, tissue remodeling, biorepository, multiscale modeling, translational research
MeSH terms: Heart Failure, Humans, Research, Stroke Volume, United States, National Heart, Lung, and Blood Institute (U.S.)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Research Priorities for Heart Failure With Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group Summary

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks